

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. A pooled analysis of 5-year data from the COMFORT-I and COMFORT-II studies demonstrated that ruxolitinib _____ prolong overall survival for patients with intermediate-2 or high-risk MF compared to those who received best available therapy or placebo.
a. Did
b. Did not
2. The SIMPLIFY-2 study investigating momelotinib versus best available therapy for patients with MF previously treated with ruxolitinib _____ demonstrate a significant reduction in spleen size with momelotinib.
a. Did
b. Did not
3. Which of the following best describes the mechanism of action of idasanutlin?
a. Hypomethylating agent
b. JAK1/2 inhibitor
c. MDM2 antagonist
4. Which of the following statements is true about ruxolitinib in the treatment of MF?
a. It is associated with an increased risk of infection
b. It improves anemia
c. It is associated with thrombocytopenia
d. All of the above
e. Both b and c
f. Both a and c
5. The JAKARTA-2 study investigated the JAK2 inhibitor fedratinib in the _____ setting for patients with MF.
a. First-line
b. Second-line
6. The CYTO-PV study evaluating the intensity of cytoreductive therapy to prevent cardiovascular events in patients with PV demonstrated a significantly lower rate of cardiovascular death and major thrombosis with a hematocrit target of _____ compared to the arm with a hematocrit target of _____.
a. Less than 45%; 45% to 50%
b. 45% to 50%; less than 45%
7. Results from the MPD-RC 112 study comparing front-line pegylated interferon alpha-2a to hydroxyurea for patients with high-risk PV or ET demonstrated higher response rates in the interferon arm.
a. True
b. False
8. Patients experiencing benefit with JAK inhibitor therapy should immediately discontinue treatment when the response to therapy begins to diminish.
a. True
b. False
9. In a retrospective analysis, an improvement in overall survival was not reported after allogeneic hematopoietic stem cell transplant among patients with MF and an intermediate-1 risk score.
a. True
b. False
10. Which of the following drug types best describes the mechanism of action of PRM-151?
a. Antifibrotic immunomodulator
b. JAK2 inhibitor
c. PI3-kinase inhibitor